ATE409031T1 - Tablettenformulierungen von venlafaxin mit verzögerter freisetzung - Google Patents

Tablettenformulierungen von venlafaxin mit verzögerter freisetzung

Info

Publication number
ATE409031T1
ATE409031T1 AT04765928T AT04765928T ATE409031T1 AT E409031 T1 ATE409031 T1 AT E409031T1 AT 04765928 T AT04765928 T AT 04765928T AT 04765928 T AT04765928 T AT 04765928T AT E409031 T1 ATE409031 T1 AT E409031T1
Authority
AT
Austria
Prior art keywords
venlafaxine
sustained
release tablet
tablet formulations
relates
Prior art date
Application number
AT04765928T
Other languages
English (en)
Inventor
Michael Rowley
Angela Potts
Edward Sims
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE409031T1 publication Critical patent/ATE409031T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04765928T 2003-10-13 2004-10-12 Tablettenformulierungen von venlafaxin mit verzögerter freisetzung ATE409031T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03256439A EP1523981A1 (de) 2003-10-13 2003-10-13 Venlafaxine-Zubereitungen mit verlängerter Freisetzung

Publications (1)

Publication Number Publication Date
ATE409031T1 true ATE409031T1 (de) 2008-10-15

Family

ID=34354597

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765928T ATE409031T1 (de) 2003-10-13 2004-10-12 Tablettenformulierungen von venlafaxin mit verzögerter freisetzung

Country Status (15)

Country Link
US (1) US20050136109A1 (de)
EP (2) EP1523981A1 (de)
KR (1) KR20060118481A (de)
CN (1) CN1889939A (de)
AT (1) ATE409031T1 (de)
AU (1) AU2004283439A1 (de)
CA (1) CA2546203A1 (de)
CO (1) CO5690567A2 (de)
DE (1) DE602004016761D1 (de)
DK (1) DK1677776T3 (de)
EC (1) ECSP066564A (de)
ES (1) ES2313059T3 (de)
NO (1) NO20062143L (de)
WO (1) WO2005039555A1 (de)
ZA (1) ZA200603822B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
MXPA04008100A (es) * 2002-02-21 2005-06-17 Biovail Lab Int Srl Formulaciones de liberacion modificada de al menos una forma de tramadol.
PL377473A1 (pl) * 2002-11-28 2006-02-06 Themis Laboratories Private Limited Sposób produkcji mikropeletek o przedłużonym uwalnianiu zawierających chlorowodorek wenlafaksyny
EP1473030B2 (de) † 2003-05-02 2014-05-14 Dexcel Ltd. Tablettenzubereitung mit verlängerter Freisetzung von Venlafaxin
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
EP2276473B1 (de) 2008-04-18 2016-09-14 Intec Pharma Ltd. Verabreichung gastroretentiver arzneimittel für carbidopa/levodopa
CA2745741A1 (en) 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
EP2726066B1 (de) 2011-06-28 2021-03-31 Neos Therapeutics, LP Dosisformen für amphetamin zur oralen verabreichung
CN109771380A (zh) * 2017-11-10 2019-05-21 连云港恒运药业有限公司 去甲文拉法辛盐酸盐药物组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
AR039164A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Sales de venlafaxina de baja solubilidad en agua
IL149055A0 (en) * 2002-04-09 2002-11-10 Karma Pharm Ltd Extended release composition comprising as active compound venlafaxine hydrochloride
BR0311693A (pt) * 2002-06-10 2005-03-22 Wyeth Corp Sal de formato de o-desmetil-venlafaxina

Also Published As

Publication number Publication date
CN1889939A (zh) 2007-01-03
CO5690567A2 (es) 2006-10-31
EP1523981A1 (de) 2005-04-20
ES2313059T3 (es) 2009-03-01
DK1677776T3 (da) 2009-01-19
KR20060118481A (ko) 2006-11-23
EP1677776B1 (de) 2008-09-24
US20050136109A1 (en) 2005-06-23
DE602004016761D1 (de) 2008-11-06
EP1677776A1 (de) 2006-07-12
ZA200603822B (en) 2008-05-28
ECSP066564A (es) 2006-10-17
CA2546203A1 (en) 2005-05-06
NO20062143L (no) 2006-07-07
AU2004283439A1 (en) 2005-05-06
WO2005039555A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
NO20062143L (no) Tablettformuleringer av venlafaxin med forlenget frigjoring
ATE454138T1 (de) Tablette mit modifizierter freisetzung von bupropion hydrochlorid
CY1106929T1 (el) Κρυσταλλικες μορφες υδροχλωριδιου (-)-(1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλοπροπυλο)-φαινολης
DE602005027540D1 (de) Feste formulierungen von ospemifen
NO20042807L (no) Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
BR0308452A (pt) composições farmacêuticas e métodos de preparação de composição farmacêutica
BRPI0409063A (pt) pró medicamentos de inibidor de pi-3 cinase
CY1108823T1 (el) Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3
SE0101675D0 (sv) Novel composition
DK1656372T3 (da) 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
NO20033384D0 (no) Farmasöytisk formulering
UY28671A1 (es) Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
NO20052310D0 (no) Posisjons isomerer av PEG IFN alfa 2A.
NO20033785L (no) Farmasöytisk formulering
UY27548A1 (es) Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas
HN2002000198A (es) Composiciones farmaceuticas de amlodipina y atorvastatina
ECSP044999A (es) Agentes antidiabeticos
MA31430B1 (fr) Formulation a liberation prolongee de nevirapine
DE502004005560D1 (de) Pharmazeutische formulierungen enthaltend hochreine basen von 3,3-diphenylpropylaminmonoestern
DK1778623T3 (da) Derivater af 1-phenylalkancarboxylsyrer til behandling af neurodegenerative sygdomme
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
ATE352305T1 (de) Stabile pharmazeutische zusammensetzungen mit desloratadine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties